A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Relapsed/Refractory Primary Central Nervous System Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou, Zhejiang, China
Contact: Study coordinator (Wenbin Qian) · qianwb@zju.edu.cn · +8613605801032

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Selinexor in Combination With MTX+Ritu to Treat R/R CNSL

Central Nervous System Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Hefei, China · Beijing, China

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Relapsed/Refractory Primary Central Nervous System Lymphoma

Abroad (travel likely)RecruitingPHASE3

Phoenix, United States · Scottsdale, United States

DALY II USA/ MB-CART2019.1 for DLBCL

Refractory Diffuse Large B Cell Lymphoma (DLBCL) · Relapsed Diffuse Large B Cell Lymphoma · High Grade B-cell Lymphoma (HGBCL)

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Gilbert, United States

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Primary Central Nervous System Lymphoma · Secondary Central Nervous System Lymphoma · Relapsed Cancer

Abroad (travel likely)RecruitingPHASE2

Miami, United States